Having trouble accessing articles? Reset your cache.

With established foothold in Japan, Amgen takes over JV from Astellas

Amgen will take over full ownership of the 2013 JV it launched with Astellas in Japan but the two will continue to co-promote Amgen’s three drugs in the country. The U.S. biotech has used its experience with Astellas to get its commercial footing in the region

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers